I have stuck to Momenta's story and it has paid off. In our view, MNTA is still vastly undervalued. With these type of revenues sustained throughout 2011, Momenta could see EPS of around $3.50 or higher for fiscal year 2011. We can't even think of another biotech stock under $1 billion in marketcap that is doing anything close to this in revenue. In a recent note out of Cowen & Co., they reiterated their belief that "Momenta's M-Enoxaprin is worth mid $20's to shares", Teva’s Lovenox ANDA is not a real threat and the possibility of a settlement in the Copaxone litigation with Momenta. Also, consider that TEVA recently stated they won't comment upon their ANDA until they get approval. Now that's a 180 degree turn from their previous pumping back in July about "being close". It suggests to us very serious problems with their Lovenox program and could spell the end of it; a cold shutdown so to speak. All of those reasons fully support our belief that Momenta is undervalued and should be well north of $20. As usual, we will keep you updated on the goings on about at Momenta.